Irkutsk
Ulan-Ude

Blagoveshchensk
Chita
Yakutsk

Birobidzhan
Vladivostok
Khabarovsk

Magadan
Yuzhno-Sakhalinsk

Anadyr
Petropavlovsk-
Kamchatsky
Moscow

This text is translated into Russian by google automatic human level neural machine.
EastRussia is not responsible for any mistakes in the translated text. Sorry for the inconvinience.
Please refer to the text in Russian as a source.

Pharmaceutical companies want to stop the production of vital drugs

Pharmaceutical companies want to stop the production of vital drugs
Photo: pixabay.com
Pharmaceutical companies warned the Russian Ministry of Industry and Trade about the possible cessation of the release of cheap drugs from the list of vital drugs. It is not beneficial for them to produce more than 50 drugs.

According to "Merchant”, Several drug manufacturers, including“ Dalkhimpharm ”, announced that due to the low maximum allowable price, the production of more than fifty names is unprofitable. Among the drugs - paracetamol, glucose solution, ibuprofen, diphenhydramine. For example, the production cost of a paracetamot package is 17,21 rubles, and in pharmacies its price should not exceed 12,05 rubles. 

The pharmaceutical market is preparing for a crisis due to the ruble devaluation and the coronavirus pandemic, which have complicated import. In addition to delivery problems, imported substances for the production of drugs have become more expensive.

The problems in the pharmaceutical industry began back in 2009. Then they set the prices for drugs from the list of vital and essential for medical use, allowing the price of drugs to be indexed to the level of annual inflation. After that, in 2014, due to the depreciation of the ruble, several drugs have already left the Russian market due to unprofitability.
September 23: current information on coronavirus in the Far East
Digest of regional events and latest statistics